美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

罗氏控股

45.15

+0.47501.06%

成交量：91.44万

成交额：4,104.45万

市值：2,876.19亿

市盈率：29.11

高：45.15

开：44.54

低：44.50

收：44.67

52周最高：45.94

52周最低：34.10

股本：63.71亿

流通股本：63.71亿

量比：0.76

换手率：0.01%

股息：1.53

股息率：3.39%

每股收益(TTM):1.55

每股收益(LYR):2.14

净资产收益率：31.32%

总资产收益率：13.30%

市净率：7.95

市盈率(LYR):21.13

数据加载中...

总览公司新闻公告

周三值得关注的股票：耐克、Lithium Americas Corp.、ARM Holdings、西方石油

罗氏(RHHBY.US)减肥药CT-388明年推进后期试验挑战礼来、诺和诺德主导地位

罗氏(RHHBY.US)乳腺癌新药三期试验达主要终点延长晚期患者无进展生存期

罗氏(RHHBY.US)将以高达35亿美元收购89bio(ETNB.US) 加码减肥药市场

罗氏(RHHBY.US)4亿美元加码IBD领域开发临床前口服小分子

特朗普拟对进口药品征收高额关税，谁最可能受影响？

智通财经网

罗氏控股周二逆市下挫表现逊于大盘

华尔街洞察

罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理

罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准

罗氏(RHHBY.US)宣布肝癌III期临床研究TALENTACE达到主要研究终点

罗氏(RHHBY.US)公布“帕妥珠单抗”乳腺癌Ⅲ期研究最新数据

罗氏(RHHBY)宣布投资超20亿人民币在沪新建生物制药生产基地

罗氏(RHHBY.US)格菲妥单抗新适应症在华获批

罗氏(RHHBY)计划未来五年在美国投资500亿美元

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/RHHBY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RHHBY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","market":"US","secType":"STK","nameCN":"罗氏控股","latestPrice":45.145,"timestamp":1760728320000,"preClose":44.67,"halted":0,"volume":914438,"delay":15,"floatShares":6371000000,"shares":6371000000,"eps":1.550894,"marketStatus":"交易中","change":0.475,"latestTime":"10-17 15:12:00 EDT 延时","open":44.54,"high":45.15,"low":44.5,"amount":41044492.020406,"amplitude":0.014551,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":1.550894,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1760731200000},"marketStatusCode":2,"adr":0,"adrRate":0.125,"exchange":"OTCQX","adjPreClose":44.67,"volumeRatio":0.76339},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RHHBY\",,,,,undefined,":{"symbol":"RHHBY","floatShares":6371000000,"roa":"13.30%","roe":"31.32%","lyrEps":2.136203,"volumeRatio":0.76339,"shares":6371000000,"dividePrice":1.529953,"high":45.15,"amplitude":0.014551,"preClose":44.67,"low":44.5,"week52Low":34.103,"pbRate":"7.95","psRate":"3.59","week52High":45.94,"institutionHeld":0.0396,"latestPrice":45.145,"eps":1.550894,"divideRate":0.03389,"volume":914438,"delay":15,"ttmEps":1.550894,"open":44.54,"prevYearClose":34.88,"prevWeekClose":45.66,"prevMonthClose":41.81,"prevQuarterClose":41.81,"fiveDayClose":45.66,"twentyDayClose":41.79,"sixtyDayClose":41.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RHHBY\",params:#limit:5,,,undefined,":[{"date":"2025-03-28","symbol":"RHHBY","amount":0.855932,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-28","defaultRemindTime":1743168600000,"name":"罗氏控股","lastCurrency":null,"lastExecuteDate":null,"recordDate":null,"payableDate":"2025-03-28","currency":"USD","dateTimestamp":1743134400000,"payDate":null},{"date":"2024-07-25","symbol":"RHHBY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1721894400000,"name":null,"time":"","dateTimestamp":1721880000000,"actualEps":null},{"date":"2024-03-14","symbol":"RHHBY","amount":0.8751559,"announcedDate":null,"type":"dividend","market":"US","newRecordDate":"2024-03-15","defaultRemindTime":1710423000000,"name":"罗氏控股","recordDate":null,"payableDate":"2024-03-15","currency":"USD","dateTimestamp":1710388800000,"payDate":null},{"market":"US","date":"2024-02-01","symbol":"RHHBY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1706763600000,"reportTimeType":"","actualEps":null},{"date":"2023-07-27","symbol":"RHHBY","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690444800000,"name":null,"time":"盘前","dateTimestamp":1690430400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RHHBY\",market:\"US\",,,undefined,":[{"executeDate":"2016-03-02","recordDate":"2016-03-04","paymentDate":"2016-04-22","value":0.837655,"currency":"USD"},{"executeDate":"2019-03-07","recordDate":"2019-03-08","paymentDate":"2019-03-18","value":0.691071,"currency":"USD"},{"executeDate":"2020-03-19","recordDate":"2020-03-20","paymentDate":"2020-03-30","value":0.7280819,"currency":"USD"},{"executeDate":"2021-03-18","recordDate":"2021-03-19","paymentDate":"2021-03-29","value":0.8108518,"currency":"USD"},{"executeDate":"2022-03-17","recordDate":"2022-03-18","paymentDate":"2022-03-28","value":1.2649619,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RHHBY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.125,"buy":0.375,"hold":0.375,"sell":0.125,"strongSell":0,"meanLabel":"BUY","meanPercent":0.375,"analysts":8,"updateTime":1759550400000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"RHHBY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1190959042","title":"周三值得关注的股票：耐克、Lithium Americas Corp.、ARM Holdings、西方石油","url":"https://stock-news.laohu8.com/highlight/detail?id=1190959042","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190959042?lang=zh_cn&edition=fundamental","pubTime":"2025-10-01 17:07","pubTimestamp":1759309631,"startTime":"0","endTime":"0","summary":"Lithium Americas Corp.：美国政府周二表示将持有这家加拿大公司及其内华达州采矿项目各5%的股份。股价在盘前交易中大涨约三分之一。耐克：这家零售商上季度销售出现意外增长，但将本财年关税成本预测上调至15亿美元。ARM Holdings：美国法院驳回了这家芯片设计公司对高通旗下子公司违反许可协议的指控。ARM Holdings股价在开盘前下跌约2%。这一消息周二也推高了美国制药股。西方石油股价在盘前交易中上涨超过1%。Acuity Brands Inc、Cal-Maine Foods和康尼格拉预计将在开盘前公布业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1917777945.USD","IE0034235303.USD","IE00B19Z3B42.SGD","LU0980610538.SGD","RHHBY","BK4604","IE00BKDWB100.SGD","BK4519","BK4559","LU1974910355.USD","SG9999015978.USD","IE00B1XK9C88.USD","LU0130102774.USD","LU0109394709.USD","LU0787776722.HKD","LU2098885051.SGD","LU0029864427.USD","LU0868494708.USD","BK4612","IE00B19Z3581.USD","BK4532","BK4168","BK4527","AYI","LU1201861249.SGD","IE00BVYPNP33.GBP","LU1035775433.USD","CAG","BK4605","LU0823411888.USD","LU0310800379.SGD","LU2168564149.EUR","GB00BDT5M118.USD","LU2462157665.USD","LU1084165304.USD","LU1119994496.HKD","BK4176","IE00BVYPNQ40.USD","QCOM","IE00BWXC8680.SGD","IE00B3S45H60.SGD","BK4550","LU0640476718.USD","IE00BKVL7J92.USD","LU0683600562.USD","LU1093756168.USD","BK4543","BK4212","SG9999001424.SGD","BK4573","LU2236285917.USD","LU1366333091.USD","LU0203345920.USD","LU1093756325.SGD","LU1829250122.USD","BK4566","IE00BK4W5L77.USD","LU0971096721.USD","BK4568","BK4609","LU2456880835.USD","IE00BMPRXQ63.HKD","LU0786609619.USD","BK4581","LU2168564222.USD","LU0251142724.SGD","LU0256863811.USD","LU0149725797.USD","BK4007","OXY","BK4201","BK4533","LU0648001328.SGD","LU0417517546.SGD","IE000M9KFDE8.USD","ARM","LU0210528500.USD","SG9999015952.SGD","LU1363072403.SGD","BK4599","IE00BZ1G4Q59.USD","BK4512","LU0079474960.USD","LU0320765992.SGD","AZN","BK4524","LU0053666078.USD","LU2168563687.JPY","LU0048573561.USD","LU1069344957.HKD","IE0002270589.USD","LU1823568750.SGD","SG9999015986.USD","BK4534","IE00BSNM7G36.USD","LU2168564495.EUR","LU0868494617.USD","LU0348723411.USD","LU1280957306.USD","CALM","BK4585","LU0708994859.HKD","LU1074936037.SGD","IE00BMPRXN33.USD","AES","BK4105","LU0889565916.HKD","LU1303367103.USD","LU1914381329.SGD","LU0081259029.USD","LU0234572021.USD","LU0154236417.USD","BK4575","BK4558","BK4579","IE00BGHQDM52.EUR","IE00BYQQ9H92.USD","BK4545","SG9999015945.SGD","LU1571399168.USD","LU2417539215.USD","IE00BK4W5M84.HKD","03165","NKE","LU0742534661.SGD","LU2487616109.SGD","LU0157215616.USD","BK4588","IE00BFXG0V08.USD","LU2106854487.HKD","LU0203347892.USD","LU0251131958.USD","LU0234570918.USD","BK4554","IE00B775SV38.USD","IE00BMPRXR70.SGD","LU1261432733.SGD","BRK.B","NVO","LU0128525929.USD","BK4141","BK4598","BK4515","LU0061475181.USD","IE00B7SZLL34.SGD","LU0054578231.USD","BK4096","LU0170899867.USD","IE00BJLML261.HKD","LU2168564065.EUR","LU1046421795.USD","LAC","LU1267930573.SGD","LU2023250504.SGD","LU2247934214.USD","LU0942090050.USD","BK4561","BK4146"],"gpt_icon":1},{"id":"2569788388","title":"罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2569788388","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569788388?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 17:31","pubTimestamp":1758533496,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来、诺和诺德等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。截至上周五，罗氏股价收涨1.46%，年内累计涨幅约5.4%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"c8c015636e69da2c01039595706c31dc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347947.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1069344957.HKD","SG9999014898.SGD","LU1267930730.SGD","LU2471134879.HKD","LU1366192091.USD","LU0823434740.USD","LU2264538146.SGD","LU1868836591.USD","LU2236285917.USD","LU0353189680.USD","LU0203201768.USD","LU2063271972.USD","SG9999015986.USD","LU1720051108.HKD","LU0786609619.USD","LU0320765992.SGD","LU1712237335.SGD","LU1291159041.SGD","BK4588","LU2602419157.SGD","SG9999001176.USD","SG9999014880.SGD","IE00B4R5TH58.HKD","03165","LU1232071149.USD","LU0316494557.USD","SG9999015945.SGD","RHHBY","LU2491050071.SGD","LU2108987350.USD","LU1917777945.USD","LU2462157665.USD","LU0385154629.USD","LU0708995401.HKD","LU0354030438.USD","LU1551013425.SGD","SGXZ57979304.SGD","LU2456880835.USD","BK4581","LU2746668974.SGD","LU2237443978.SGD","SG9999014914.USD","LU0471298777.SGD","LU0823416689.USD","BK4007","LU0323591593.USD","LU2265009873.SGD","LU0006306889.USD"],"gpt_icon":1},{"id":"2569788801","title":"罗氏(RHHBY.US)乳腺癌新药三期试验达主要终点 延长晚期患者无进展生存期","url":"https://stock-news.laohu8.com/highlight/detail?id=2569788801","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569788801?lang=zh_cn&edition=fundamental","pubTime":"2025-09-22 17:20","pubTimestamp":1758532835,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，瑞士制药商罗氏宣布Giredestrant治疗乳腺癌的III期evERA研究取得了积极结果。Giredestrant帮助患有特定类型晚期乳腺癌的患者延长了疾病未恶化的生存期。该药物能否延长患者生命尚待观察，但罗氏在周一的声明中指出存在\"明显的积极趋势\"。这些结果是罗氏今年计划公布的一系列药物试验数据的一部分，这些数据将决定罗氏未来的竞争力。研究的主要终点是研究者评估的意向治疗人群和ESR1突变亚组的无进展生存期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1347951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","03165","RHHBY"],"gpt_icon":0},{"id":"2568756421","title":"罗氏(RHHBY.US)将以高达35亿美元收购89bio(ETNB.US) 加码减肥药市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2568756421","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568756421?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 15:28","pubTimestamp":1758180528,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏将以高达35亿美元的价格收购生物制药公司89bio，这是该瑞士制药商进军减肥药及相关疗法市场的最新举措。罗氏将以每股14.50美元的现金收购89bio，股权总价值约为24亿美元。罗氏计划加快其实验性减肥药物的研发进程，这些药物在较小规模的试验中取得的数据好坏参半，但目前正朝着临床开发的关键最后阶段迈进。罗氏近期最大的几笔交易都与肥胖症相关。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1346733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ETNB","BK4585","RHHBY","BK4007","BK4139","03165"],"gpt_icon":0},{"id":"2564007528","title":"罗氏(RHHBY.US)4亿美元加码IBD领域 开发临床前口服小分子","url":"https://stock-news.laohu8.com/highlight/detail?id=2564007528","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564007528?lang=zh_cn&edition=fundamental","pubTime":"2025-09-02 21:15","pubTimestamp":1756818907,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，9月2日，OMass Therapeutics宣布，已与罗氏集团成员基因泰克达成一项独家合作与许可协议，授权后者开发和商业化OMass针对炎症性肠病的临床前口服小分子项目。根据协议条款，OMass将获得2000万美元的首付款，此外还有可能获得超过4亿美元的潜在临床前、开发、商业和净销售额里程碑付款。在此合作下，OMass将主导该项目的初步临床前开发，直至候选化合物选定。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1340712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","RHHBY","BK4007","IBD"],"gpt_icon":0},{"id":"2555064777","title":"特朗普拟对进口药品征收高额关税，谁最可能受影响？","url":"https://stock-news.laohu8.com/highlight/detail?id=2555064777","media":"智通财经网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555064777?lang=zh_cn&edition=fundamental","pubTime":"2025-07-30 13:40","pubTimestamp":1753854000,"startTime":"0","endTime":"0","summary":"7月30日，美国总统特朗普即将对进口药品加征关税，这一政策可能最快于8月1日开始实施，并在未来一年或一年半内逐步提高税率。包括罗氏在内的多家药企高管近期对药品关税提出强烈批评，认为该政策将损害研发投入，并最终导致患者可获得的治疗选择减少。罗氏强调，药品和诊断应被排除在关税之外，以保护患者可及性和未来的医疗创新。但公司也表示，已做好准备应对潜在关税，通过库存调整等方式确保产品供应不受影响。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1323364.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"特朗普拟对进口药品征收高额关税，谁最可能受影响？","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["AZN","BK4535","BMY","GILD","BK4023","BK4551","SNY","MRK","GSK","PFE","VRTX","ZTS","LLY","AMGN","BK4503","NVO","NVS","BIIB","RHHBY"],"gpt_icon":1},{"id":"1199145168","title":"罗氏控股周二逆市下挫 表现逊于大盘","url":"https://stock-news.laohu8.com/highlight/detail?id=1199145168","media":"华尔街洞察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1199145168?lang=zh_cn&edition=fundamental","pubTime":"2025-07-16 00:55","pubTimestamp":1752598525,"startTime":"0","endTime":"0","summary":"瑞士股市周二遭遇普跌行情中，罗氏控股股价下跌1.0%，报收255.00瑞郎。当日瑞士基准股指SMI下跌0.3%，收报11901.32点。\n当前股价较今年3月12日创下的52周高点313.80瑞郎尚有58.80瑞郎差距。值得注意的是，当日成交量仅为69.5万股，显著低于50日平均成交量101.2万股。\n欧洲时段尾盘交易数据显示，这家医药巨头延续了近期弱势表现，在蓝筹股集体承压的环境下表现尤为疲软。技术指标显示，股价已连续三个交易日运行于关键均线下方，量能萎缩暗示市场参与度降低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","AG","03165","BK4210","BK4007"],"gpt_icon":0},{"id":"2538357447","title":"罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2538357447","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2538357447?lang=zh_cn&edition=fundamental","pubTime":"2025-05-28 15:39","pubTimestamp":1748417975,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月28日，CDE官网显示，罗氏注射用维泊妥珠单抗新适应症上市申请获受理。今年4月，罗氏在一季度报中披露，2025年将递交维泊妥珠单抗联合莫妥珠单抗二线以上DLBCL适应症的上市申请。2023年1月，维泊妥珠单抗进入中国市场，适应症为：1）联合利妥昔单抗、环磷酰胺、多柔比星和泼尼松适用于治疗既往未经治疗的DLBCL成人患者；2）联合苯达莫司汀和利妥昔单抗用于不适合接受造血干细胞移植的R/RDLBCL成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1298542.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)注射用维泊妥珠单抗新适应症国内上市申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2537732976","title":"罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2537732976","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537732976?lang=zh_cn&edition=fundamental","pubTime":"2025-05-23 08:37","pubTimestamp":1747960633,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，罗氏今日宣布，美国FDA批准Susvimo100 mg/mL用于治疗糖尿病视网膜病变。根据新闻稿，Susvimo是首个经FDA批准可持续释放、并在每9个月仅需一次补充给药的DR治疗方案，已被证实可维持患者的视力。此次FDA的批准主要基于Pavilion临床3期研究的一年期积极结果。此外，Susvimo治疗组在一年内无一例患者需要额外辅助治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296678.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"罗氏(RHHBY.US)Susvimo用于治疗糖尿病视网膜病变获FDA批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2537356603","title":"罗氏(RHHBY.US)宣布肝癌III期临床研究TALENTACE达到主要研究终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2537356603","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537356603?lang=zh_cn&edition=fundamental","pubTime":"2025-05-21 14:22","pubTimestamp":1747808533,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月21日，罗氏宣布III期TALENTACE研究达到主要研究终点，该研究评估了阿替利珠单抗、贝伐珠单抗和按需经动脉化疗栓塞术在未接受过既往全身系统治疗的不可切除肝细胞癌患者中的疗效和安全性。TALENTACE研究开创性地探索了免疫检查点抑制剂阿替利珠单抗联合抗血管生成靶向治疗贝伐珠单抗与按需TACE同期联合治疗的协同效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1295741.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK4007","RHHBY","III","03165"],"gpt_icon":0},{"id":"2535779040","title":"罗氏(RHHBY.US)公布“帕妥珠单抗”乳腺癌Ⅲ期研究最新数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2535779040","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2535779040?lang=zh_cn&edition=fundamental","pubTime":"2025-05-13 15:38","pubTimestamp":1747121922,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月13日，罗氏公布III期APHINITY研究的最终总生存期结果，该研究针对HER2阳性早期乳腺癌患者。APHINITY是一项全球性 III 期、随机、双盲、安慰剂对照、双组研究，旨在评估帕妥珠单抗联合赫赛汀联合化疗作为术后(辅助)治疗的疗效和安全性，并与赫赛汀联合化疗进行比较。包括心脏安全性在内的安全性与先前研究一致，未发现新的或意外的安全信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1292461.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2533143908","title":"罗氏(RHHBY)宣布投资超20亿人民币 在沪新建生物制药生产基地","url":"https://stock-news.laohu8.com/highlight/detail?id=2533143908","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533143908?lang=zh_cn&edition=fundamental","pubTime":"2025-05-08 17:36","pubTimestamp":1746696962,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据解放日报，罗氏制药(RHHBY)中国5月8日宣布投资20.4亿元人民币，用于在上海新建生物制药生产基地。当天投资项目启动仪式举行。企业表示，此次加码投资旨在通过强化企业在华供应链和本地化生产布局，全面强化端到端的完整医药价值产业链。项目位于张江高科技园区，用地约53亩，建筑面积约2.5万平方米。项目预计2029年正式落成，2031年正式投产。基地将用于罗视佳®（法瑞西单抗注射液）的本地化生产 ，不断满足中国患者对于创新疗法需求。","market":"fut","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"288305","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RHHBY","03165","BK4007"],"gpt_icon":0},{"id":"2533917658","title":"罗氏(RHHBY.US)格菲妥单抗新适应症在华获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2533917658","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533917658?lang=zh_cn&edition=fundamental","pubTime":"2025-05-08 10:54","pubTimestamp":1746672875,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月7日，罗氏宣布格菲妥单抗注射液新适应症上市申请已获得中国国家药监局批准，联合吉西他滨与奥沙利铂用于治疗不适合自体造血干细胞移植的复发或难治性弥漫大B细胞淋巴瘤非特指型成人患者。格菲妥单抗是一款靶向CD20和CD3的双特异性T细胞衔接蛋白。该产品于2023年11月在中国获批上市，用于治疗既往接受过至少两线系统性治疗的复发或难治性DLBCL成人患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1290640.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"罗氏(RHHBY.US)格菲妥单抗新适应症在华获批","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03165","BK4007","RHHBY"],"gpt_icon":0},{"id":"2529634009","title":"罗氏(RHHBY)计划未来五年在美国投资500亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529634009","media":"金吾财讯","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529634009?lang=zh_cn&edition=fundamental","pubTime":"2025-04-22 16:41","pubTimestamp":1745311271,"startTime":"0","endTime":"0","summary":"金吾财讯 | 据外媒报道，罗氏控股(RHHBY)未来五年将在美国投资500亿美元用于制药和诊断业务，相关计划包括扩大和升级肯塔基州、印第安纳州、新泽西州、俄勒冈州和加利福尼亚州的制造和分销能力。罗氏还计划建立一家生产工厂，以支持下一代减肥药的扩产，但没有透露工厂的位置。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NTA4OTM0NjA2MTc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"287712","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03165","RHHBY"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}]}}